Peptide Library

FDA-approved

Sexual & reproductive

Degarelix

Evidence

FDA approved

Class

GnRH antagonist

/

Degarelix

KEY TAKEAWAY

Degarelix is a ten-amino-acid GnRH antagonist. It is sold as Firmagon. The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GnRH antagonist

Approved for

Advanced prostate cancer

Key fact

The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.

Route

Monthly subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Degarelix is a ten-amino-acid GnRH antagonist. It is sold as Firmagon.

How it works

How it works

It blocks GnRH receptors, which quickly lowers testosterone without the early surge seen with GnRH agonists.

Regulatory status

Regulatory status

The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.

What it is used for

What it is used for

Advanced prostate cancer.

Side effects and risks

Side effects and risks

Hot flashes, injection-site reactions, weight gain and liver enzyme increases are common. Long-term testosterone lowering affects bone and heart health.

Citations

Citations

U.S. FDA prescribing information for Degarelix. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo